Market Research Report
Lasmiditan (Migraine) - Forecast and Market Analysis to 2023
|Published by||GlobalData||Product code||301158|
|Published||Content info||55 Pages
|Lasmiditan (Migraine) - Forecast and Market Analysis to 2023|
|Published: March 31, 2014||Content info: 55 Pages||
This publication has been discontinued on January 18, 2018.
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
CoLucid Pharmaceuticals is developing Lasmiditan under a licensing agreement with Eli Lilly for the treatment of acute migraine. Lasmiditan is being developed to address the needs of two groups of patients, those with risk or diagnosis of cardiovascular disease, and those who have not had adequate efficacy from triptans. The drug is a neurally acting anti-migraine agent (NAAMA) that does not cause vasoconstriction, unlike other acute therapies such as the triptans, which also interact with 5-HT receptors located in the central and peripheral nervous systems.